Is generic semaglutide available in 2026?
No FDA-approved generic semaglutide exists yet. Ozempic's core patents run into the late 2020s. Here's how compounded semaglutide fits — and what's changing.
Updated May 18, 2026 · 4 min read
No. There is no FDA-approved generic semaglutide as of 2026. Novo Nordisk's core patents on the semaglutide molecule don't expire until the late 2020s at the earliest, meaning a true generic — identical formulation, FDA's ANDA review process, same manufacturing standards as brand — is years away.
What does exist is compounded semaglutide, which is related but different. Here's what that distinction actually means.
Generic vs. Compounded: Not the Same Thing
The terms get conflated constantly, but they describe fundamentally different products.
Generic semaglutide would require:
- Patent expiration on the semaglutide active ingredient and its formulation
- A competing manufacturer filing an Abbreviated New Drug Application (ANDA) with the FDA
- FDA approval of that ANDA, confirming the generic is bioequivalent to the brand product
- Manufacturing inspection and approval
None of those steps have happened. There are no FDA-approved generic versions of Ozempic, Wegovy, or Rybelsus in 2026.
Compounded semaglutide is:
- Semaglutide bulk active pharmaceutical ingredient (API) purchased from a third-party supplier
- Mixed and prepared by a licensed 503A (patient-specific) or 503B (FDA-registered outsourcing facility) pharmacy
- Not FDA-reviewed as a finished product — only the API has been assessed
- Legally produced under Section 503A/503B of the Federal Food, Drug, and Cosmetic Act, under specific conditions
Compounding has been legal for years under shortage provisions. The FDA added semaglutide to its shortage list in 2022 due to Wegovy supply constraints, which expanded the legal basis for compounding. As supply improved, FDA began moving toward restricting compounding of shortage-list drugs — a process that has been contested legally and is still evolving as of 2026.
The Patent Timeline
Novo Nordisk's patent portfolio around semaglutide is layered and complex — typical for a blockbuster drug. The core active ingredient patent, the formulation patents, and delivery mechanism patents all have different expiration dates.
The earliest meaningful US patent expiration for the semaglutide compound itself is approximately 2030–2032, depending on which patents a challenger would need to overcome. Secondary patents on specific formulations and devices (the autoinjector pens) could extend market exclusivity further.
This is why branded semaglutide faces no generic competition pressure yet, and why compounding has filled the cost gap during the shortage period.
What "Compounded" Means in Practice
If you're currently using or considering compounded semaglutide, the practical differences from the brand pens:
| Feature | Brand (Ozempic/Wegovy) | Compounded |
|---|---|---|
| FDA reviewed (finished product) | Yes | No |
| Dosing form | Autoinjector pen | Vial + syringe |
| Concentrations available | Standardized by pen | Variable (pharmacy-set) |
| Cost without insurance | ~$1,000+/month | ~$150–400/month |
| Manufacturing oversight | Full GMP | 503A/503B varies |
| Legal status (2026) | Fully legal | Restricted; evolving |
The biggest practical risk with compounded semaglutide isn't the active ingredient — semaglutide is semaglutide — but dosing accuracy and sterility. Vials require reconstitution (or arrive pre-mixed) and demand careful dosing math. For help with that math, the reconstitution calculator handles the conversion.
There have been documented cases of incorrectly concentrated compounded products causing overdoses. This doesn't mean compounded semaglutide is categorically unsafe, but it underscores why quality source selection and correct dosing technique matter more than they do with autoinjector pens.
The Regulatory Situation in 2026
FDA's stance on compounded GLP-1 drugs has been in flux. Key inflection points:
- 2022–2024: Wegovy on FDA shortage list; 503A and 503B compounding broadly legal under shortage provisions
- Late 2024/Early 2025: FDA removed Wegovy from shortage list; began enforcement posture against 503B outsourcing facility compounding of semaglutide specifically
- 2025–2026: Legal challenges from compounding pharmacies and telehealth platforms created ongoing uncertainty; enforcement timelines shifted multiple times
The practical result: compounded semaglutide access has become patchier than it was in 2023–2024. Some telehealth platforms that previously dispensed it freely have paused or restricted offerings. Others continue under 503A individual pharmacy provisions. The landscape varies by state and by provider.
If you're relying on compounded semaglutide for cost reasons, it's worth staying current on your provider's status and having a contingency plan if their access changes.
When Might Genuine Generics Arrive?
The earliest realistic scenario for an FDA-approved generic semaglutide would be after 2031–2032, assuming a manufacturer files an ANDA as soon as the first core patent expires and receives FDA approval within the typical 12–24 month review window. That's a best-case scenario.
Some industry observers expect Novo Nordisk to pursue supplemental patents and formulation protections that could extend effective exclusivity longer — as is common in the pharmaceutical industry.
For now, the cost options available to people who can't access insurance-covered brand semaglutide are: manufacturer patient assistance programs (Novo Nordisk Norvo Care), GoodRx and similar discount platforms, insurance appeals, and compounded semaglutide (with the caveats above).